Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18008 ↗Kurz gefasst
Leserbrief in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Raphael Mohr und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Disease Progression. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
LINKED CONTENT This article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.17985
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Raphael Mohr, Frank Tacke
Zitieren
APA
Mohr, R., Tacke, F., & Roderburg, C. (2024). Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18008
Vancouver
Mohr R, Tacke F, Roderburg C. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18008
BibTeX
@article{Mohr2024,
author = {Mohr, Raphael and Tacke, Frank and Roderburg, Christoph},
title = {Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18008}
}
EUVIMED